Abstract:Original Research Article Metformin hydrochloride (MET) is an oral hypoglycaemic agent which improves glucose tolerance in patients with type 2 diabetes and diminishes basal plasma levels of glucose. The aim of this study was to develop and optimize MET matrix tablets for SR application. The SR matrix tablet of MET was prepared by wet granulation technique using Sodium carboxymethyl cellulose and hydroxyl propyl methylcellulose of different viscosity grades (HPMC K4M, HPMC K15M, and HPMC K100M). The influence of varying the polymer ratios was evaluated. The excipients used in this study did not modify physicochemical properties of the drug. MET has relatively short plasma half-life, low absolute bioavailability. The need for the administration 2 to 3 times a day when larger doses are required can decrease patient fulfilment. SR formulation that would maintain plasma level for 8-12 h might be sufficient for daily dosing of MET. SR products are needed for MET to prolong its duration of action and to improve patient compliances. The developed formulation of tablet (F1 to F6) was evaluated for pre-compression and post–compression method. The results of all parameter were found to be within the limits. The optimized formulations (F6) were subjected to stability studies and shown there were no significant changes in drug content, physicochemical parameters and release pattern. Assay of the pure drug and formulation was carried out by using UV and RP-HPLC method. The in vitro drug dissolution study was carried out using USP apparatus Type I, Basket method and the release mechanisms were explored. Mean dissolution time is used to characterize drug release rate from a dosage form and indicates the drug release is retarding efficiency of the polymer. The in vitro release studies exhibits the release up to 94.8%, over a prolonged period of time which confirms the extended release profile of formulation (F6) after 12 hrs as compared to marketed formulation, invitro drug release data obtained were fitted to various release model excess the possible mechanism of the drug release. In conclusion, development of MET SR tablets is a good approach to sustain the release rate to overcome frequent administration and also to release the drug for prolongs period thus maintaining plasma level above the MEC for desired time period. Further the efficacy of the developed formulations has to be assessed by pharmacokinetic studies in humans. Keyword: Metformin hydrochloride, SR matrix tablet, HPMC K100M, Wet granulation technique, In vitro drug dissolution. Copyright @ 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

Understanding the influence of thermal cycles on the stability of metformin HCl in presence of Sitagliptin phosphate monohydrate and polyvinyl alcohol

Solid-State Characterization of Different Crystalline Forms of Sitagliptin

Impact of Hot-Melt Extrusion on Glibenclamide's Physical and Chemical States and Dissolution Behavior: Case Studies with Three Polymer Blend Matrices

Stability-Indicating RP-HPLC Method for Simultaneous Determination of Metformin Hydrochloride and Sitagliptin Phosphate in Dosage Forms

Formulation Development of Sustained Release Matrix Tablet Containing Metformin Hydrochloride and Study of Various Factors Affecting Dissolution Rate

BIOAVAILABILITY AND POLYMORPHIC STABILITY CHALLENGES AFFECTING DRUG PRODUCT’S POTENTIAL: A CRITICAL EVALUATION AND PERTINENT SOLUTION

Influence of water-soluble polymers on the in vitro performance of floating mucoadhesive tablets containing metformin

Investigation of the Fused Deposition Modeling Additive Manufacturing I: Influence of Process Temperature on the Quality and Crystallinity of the Dosage Forms

Formulation and Evaluation of Extended Release Oral Suspension of Metformin Hydrochloride

Physicochemical Investigations and Stability Studies of Amorphous Gliclazide

The Impact of Various Poly(vinylpyrrolidone) Polymers on the Crystallization Process of Metronidazole

Advancing Thermal Stability Analysis of Haloperidol: Integrative Approaches and Optimization Strategies for Enhanced Pharmaceutical Formulations

Stability-indicating high-performance thin-layer chromatography method development and validation for dapagliflozin propanediol monohydrate, vildagliptin, and metformin hydrochloride in active pharmaceutical ingredient and its tablet dosage form

Volumetric, ultrasonic, conductometric and UV–visible analysis of molecular interactions between metformin hydrochloride and dulcitol in aqueous solutions

FORMULATION AND EVALUATION OF METFORMIN HYDROCHLORIDE SUSTAINED RELEASE MATRIX TABLETS

The Effect of Formulation Variables on the Manufacturability of Clopidogrel Tablets via Fluidized Hot-Melt Granulation—From the Lab Scale to the Pilot Scale

Fabrication and evaluation of gelatin-PVA-co-poly(2-acrylamido-2-methylpropane sulfonic acid)-based hydrogels for extended-release of sitagliptin and metformin by employing response surface methodology

Mechanisms of dissolution and crystallization of amorphous glibenclamide

Analytical quality by design approach for the development of high‐performance liquid chromatography method for simultaneous analysis of metformin and sitagliptin in the presence of major degradation products

A 3D printed bilayer oral solid dosage form combining metformin for prolonged and glimepiride for immediate drug delivery

Optimization of a Twin screw melt granulation process for fixed dose combination immediate release Tablets: Differential amorphization of one drug and crystalline continuance in the other